期刊文献+

辛伐他汀及阿司匹林对高血压病合并颈动脉粥样硬化的干预性的对比研究 被引量:2

下载PDF
导出
摘要 目的探讨辛伐他汀及阿司匹林对高血压病患者颈动脉粥样硬化病变和CRP的影响。方法96例高血压病合并颈动脉粥样硬化患者随机分成A、B、C3组,每组32例,A组加用辛伐他汀片20mg,每晚1次;B组加服阿司匹林肠溶胶囊75mg,每日1次;C组加服同等剂量的辛伐他汀及阿司匹林。分别于入院后及6月时测定血浆CRP、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、高频超声检测颈动脉,记录颈动脉中层厚度(IMT)、颈动脉斑块积分、斑块发生率。结果3组患者用药前后CRP浓度均有显著性降低(P<0.05),A组和C组用药前后IMT、颈动脉斑块积分、斑块发生率比较有显著降低,B组用药前后IMT、颈动脉斑块积分、斑块发生率比较无明显差异,而C组(辛伐他汀及阿司匹林组)用药后CRP的浓度和IMT、颈动脉斑块积分、斑块发生率与另外两组用药后CRP的浓度和IMT、颈动脉斑块积分、斑块发生率比较降低更为明显(P<0.05),有显著性差异。结论辛伐他汀和阿司匹林联合应用对减轻颈动脉粥样硬化及CRP的降低优于单一使用辛伐他汀或阿司匹林。
作者 徐尚志
机构地区 浙江省荣军医院
出处 《江西医药》 CAS 2008年第6期552-555,共4页 Jiangxi Medical Journal
  • 相关文献

参考文献10

  • 1Hassan A,Markus HS.Genetics and Ischaemic Stroke.Brain,2000,123: 1784
  • 2Pearson TA,Mensah GA,Alexander RW,et al.Markers of Inflammation and ardiovascularDisease:Application to Clinical and Public Health Practice:A Statement for Healthcare Professionals From the Centers for Disease Control and Prevention and the American Heart Association.Circulation,2003,107:499
  • 3RoivainenM, KajanderMV, Palosuo P,et al.Infections,Inflammation, and the Risk of Coronary Heart Disease. Circulation,2000,101:252
  • 4Li JJ,Fang CH1.Creactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.Med Hypotheses , 2004,62:499
  • 5Grundy SM,Clemen J I,Mers CN, et al. Implications of recent clinical trials for the National Cholesterol EducationProgram Adult Treatment Panel III guideline. Circulation,2004,110 (2): 227
  • 6Shepherd J,Blauw GJ,Murphy MB,et al.Pravastatin inelderly individuals at risk of vascular disease:a randomizedcontrolled trial. Lancet,2002, 360:1623
  • 7Downs JR ,ClearfieldM,Whitney E, et al.Primarg prevention of acute coronary events with lovastatin in men and womem with average choresterol levels. JAMA, 1998:1615
  • 8Rosensor RS,Tangney CC.Antiatherothrombotic properties of statins: implications for cardiovascular events reduction.JAMA,1998;279:1643
  • 9Rharbanda RK,Walfan B,Allen M,et al.Prevention of inflammationinduced endothelial dysfunction:a novel vasculo protectiveaction of aspirin. Circulation, 2003, 105:2600
  • 10刘东,黄晶,邓昌明,高大中,李增高.辛伐他汀及阿司匹林对冠心病患者C反应蛋白的影响[J].重庆医科大学学报,2002,27(3):329-330. 被引量:3

二级参考文献5

  • 1[1]Alexander RW. Inflammation and coronary artery disease [J].N Engl J Med, 1994;331:468-469.
  • 2[2]Paul M Ridker, Mary Cushman, Meir J, et al. Inflammation,Aspirin, and the risk of cardiovascular disease in apparently healthy men[J].N Engl J Med, 1997;336:973-979.
  • 3[3]Marrow DA, Rifai N, Antman EM, et al. C-reactive protein as a potent predictor of mortality indepently of and in combination with troponin T in acute coronary syndromes: a TIMI Ⅱ A substudy[J]. J AM Coll Cardiol, 1998;31:1460-1465.
  • 4[4]Rosensor RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular events reduction[J].JAMA, 1998;279:1643-1650.
  • 5[5]Ridker PM, Rifai N, Pfeifer MA, et al. Inflammation,pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels[J].Circulation, 1998; 98:839-844.

共引文献2

同被引文献6

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部